Gilead Science's remdesivir manufacturing projections 2020

Cumulative amount of remdesivir treatment courses projected to be manufactured by Gilead Sciences during 2020

Loading statistic...
Show detailed source information?
Register for free
Already a member?
Log in

Use Ask Statista Research Service

Release date

July 2020


United States

Survey time period

as of July 2020

Supplementary notes

Original manufacturing projections from January to May based on 11-vial treatment course. Projections through end of June based on average 7.78 vials per treatment course. Year-end projection based on average 6.25 vials per treatment course.
Figures reflect the cumulative amount of drug that Gilead expects to produce and are inclusive of supply allocated for clinical trials, compassionate use and expanded access programs, and any potential regulatory authorizations or approvals.

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Coronavirus: the pharma and medtech response "

Other statistics that may interest you Coronavirus: the pharma and medtech response

Pharma - before the pandemic


Treatments and vaccines


Focus: BioNTech and Moderna


Opinions on COVID-19 vaccines


Business impact


Medtech - before the pandemic


Ventilators and testing


Further related statistics


Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.